ICCC Immucell Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: ICCC

Price (delayed)

$5.05

Market cap

$39.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.75

Enterprise value

$54.85M

ImmuCell Corporation's purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate ...

Highlights
ICCC's EPS has dropped by 134% year-on-year but it is up by 7% since the previous quarter
The net income has dropped by 132% year-on-year but it rose by 8% since the previous quarter
ICCC's quick ratio has dropped by 70% year-on-year and by 35% since the previous quarter
ICCC's gross margin is down by 46% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.immucell.com
Peers: IDXX WOOF MRK ZTS

Key stats

What are the main financial stats of ICCC
Market
Shares outstanding
7.75M
Market cap
$39.14M
Enterprise value
$54.85M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.57
Price to sales (P/S)
2.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.14
Earnings
Revenue
$17.47M
EBIT
-$5.77M
EBITDA
-$3.05M
Free cash flow
-$6.56M
Per share
EPS
-$0.75
Free cash flow per share
-$0.85
Book value per share
$3.22
Revenue per share
$2.26
TBVPS
$5.64
Balance sheet
Total assets
$43.81M
Total liabilities
$18.82M
Debt
$16.69M
Equity
$24.99M
Working capital
$7.27M
Liquidity
Debt to equity
0.67
Current ratio
2.73
Quick ratio
0.75
Net debt/EBITDA
-5.15
Margins
EBITDA margin
-17.5%
Gross margin
22.1%
Net margin
-33.1%
Operating margin
-32.9%
Efficiency
Return on assets
-13.2%
Return on equity
-21.8%
Return on invested capital
-10.8%
Return on capital employed
-14.6%
Return on sales
-33%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ICCC stock price

How has the Immucell stock price performed over time
Intraday
-0.98%
1 week
0.6%
1 month
-2.13%
1 year
1.81%
YTD
-0.79%
QTD
-4.72%

Financial performance

How have Immucell's revenue and profit performed over time
Revenue
$17.47M
Gross profit
$3.87M
Operating income
-$5.75M
Net income
-$5.77M
Gross margin
22.1%
Net margin
-33.1%
The operating margin has dropped by 165% year-on-year but it rose by 16% since the previous quarter
The operating income has dropped by 150% year-on-year but it has grown by 10% since the previous quarter
Immucell's net margin has plunged by 147% YoY but it has increased by 14% from the previous quarter
The net income has dropped by 132% year-on-year but it rose by 8% since the previous quarter

Growth

What is Immucell's growth rate over time

Valuation

What is Immucell stock price valuation
P/E
N/A
P/B
1.57
P/S
2.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.14
ICCC's EPS has dropped by 134% year-on-year but it is up by 7% since the previous quarter
The company's equity fell by 18% YoY and by 3.9% QoQ
The stock's P/B is 7% less than its 5-year quarterly average of 1.7 but 5% more than its last 4 quarters average of 1.5
The stock's P/S is 25% less than its 5-year quarterly average of 3.0 and 6% less than its last 4 quarters average of 2.4
Immucell's revenue has increased by 7% QoQ but it has decreased by 6% YoY

Efficiency

How efficient is Immucell business performance
The company's return on equity has shrunk by 179% YoY but it rose by 3.5% QoQ
ICCC's return on sales has dropped by 146% year-on-year but it is up by 15% since the previous quarter
The ROA has dropped by 144% year-on-year but it is up by 8% since the previous quarter
ICCC's ROIC has dropped by 100% year-on-year but it is up by 11% since the previous quarter

Dividends

What is ICCC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ICCC.

Financial health

How did Immucell financials performed over time
ICCC's total assets is 133% higher than its total liabilities
ICCC's quick ratio has dropped by 70% year-on-year and by 35% since the previous quarter
Immucell's current ratio has decreased by 40% YoY and by 24% from the previous quarter
Immucell's debt is 33% less than its equity
The company's debt to equity has surged by 63% YoY and by 4.7% QoQ
Immucell's debt has increased by 34% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.